St Joseph Residence | |
495 Mammoth Rd, Manchester, New Hampshire 03104 | |
(603) 668-6011 | |
Name | St Joseph Residence |
---|---|
Location | 495 Mammoth Rd, Manchester, New Hampshire |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 22 |
Occupancy Rate | 86.36% |
Medicare ID (CCN) | 305088 |
Legal Business Name | Saint Joseph Residence |
Ownership Type | Non Profit - Church Related |
NPI Number | 1396724795 |
Organization Name | SAINT JOSEPH RESIDENCE |
Address | 495 Mammoth Rd, Manchester, NH 03104 |
Phone Number | 603-668-6011 |
News Archive
Morphotek, Inc., a subsidiary of Eisai Inc., announced today that it has been awarded a contract for $2.5 million from the U.S. Department of Defense (DOD) to support the continuing development of monoclonal antibody (mAb) therapies against staphylococcal-derived toxins and pathogenic staphylococcal strains.
Janssen Pharmaceuticals, Inc. today announced the results of an investigational Phase 3 study suggesting NUCYNTA ER (tapentadol) extended-release tablets were significantly more effective than placebo in providing pain management among adults with chronic moderate to severe, painful diabetic peripheral neuropathy.
CardioGenics Holdings Inc., developer of the ultra-sensitive QL Care™ Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced that CardioGenics Inc. and Merck Chimie S.A.S. have agreed on a plan to commercialize CardioGenics' proprietary paramagnetic beads, with shipments to Merck-Chimie's customers scheduled to start mid-September 2010.
A new framework for action on social marketing and public health was published today by the UK's Department of Health. Ambitions for Health sets out how we will use evidence of what motivates people to help them lead healthier lives through targeted action. This builds on the success of programmes like Health Trainers, which provides one-to-one support to help individuals tackle health issues.
› Verified 4 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Morphotek, Inc., a subsidiary of Eisai Inc., announced today that it has been awarded a contract for $2.5 million from the U.S. Department of Defense (DOD) to support the continuing development of monoclonal antibody (mAb) therapies against staphylococcal-derived toxins and pathogenic staphylococcal strains.
Janssen Pharmaceuticals, Inc. today announced the results of an investigational Phase 3 study suggesting NUCYNTA ER (tapentadol) extended-release tablets were significantly more effective than placebo in providing pain management among adults with chronic moderate to severe, painful diabetic peripheral neuropathy.
CardioGenics Holdings Inc., developer of the ultra-sensitive QL Care™ Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced that CardioGenics Inc. and Merck Chimie S.A.S. have agreed on a plan to commercialize CardioGenics' proprietary paramagnetic beads, with shipments to Merck-Chimie's customers scheduled to start mid-September 2010.
A new framework for action on social marketing and public health was published today by the UK's Department of Health. Ambitions for Health sets out how we will use evidence of what motivates people to help them lead healthier lives through targeted action. This builds on the success of programmes like Health Trainers, which provides one-to-one support to help individuals tackle health issues.
› Verified 4 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 21.95 | 14.46 |
Percentage of long-stay residents who lose too much weight | 6.94 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 41.03 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 5.56 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 1.28 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 8.54 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 4.88 | 14.2 |